Introduction
The synthesis of some aza homosteroid compounds with unu sual and interesting structures has been reported recently [1 4 ]. These compounds exhibit valuable biological activities such as cytotoxicity and antibacteria. Study of aza homosteroids indicates that the presence of the characteristic group ( NH CO ) in the aza homosteroid molecule has been demonstrated to be important in lowering toxicity and improving anti tumor activity of the com pounds in cancer treatment [5] .
Recently we designed and synthesized several new steroidal lactams with the introduction of N atom on A or D ring. Our re sults have shown that these compounds displayed a distinct cyto toxicity against different cancer cell types [6, 7] . In this study, we report that 6 hydroximino 4 aza A homo cholest 3 one (1) and 6 hydroxyl 4 aza A homo cholest 3 one (2), new steroidal lac tams were synthesized recently [8] , exerted potent cytotoxic activ ity against several cancer cells including HT 29 (colorectal adenocarcinoma), GNE 2 (nasopharyngeal carcinoma), SPC A (lung carcinoma), Tu 686 (laryngocarcinoma) and PC 3 (prostate adeno carcinoma) cancer cells. Further investigation revealed that the compounds were able to induce cancer cell apoptosis and inhibited tumor growth in athymic mice.
Materials and methods

Drug preparations
The tested compounds ( Fig. 1 ) were synthesized by previously described methods [8] . Stock solutions of the tested compounds were made immediately before use.
Biological assays
Cell culture and assay for cell viability GNE 2 (nasopharyngeal carcinoma), SPC A (lung carcinoma) and Tu 686 (laryngic carcinoma) cell lines were obtained by Guangxi Medical University (China); HT 29 (colorectal adenocarci noma) and PC 3 (prostate adenocarcinoma) cancer cells were ob tained by ATCC, Manassas, VA. Cells were grown in RPMI 1640 supplemented with 10% cosmic calf serum (Hyclone) and antibiot ics in a humidified atmosphere of 5% CO 2 at 37°C. The viability of these cells was determined using the colorimetric CellTiter 96 aqueous Cell Proliferation Assay (MTT) according to the instruc tions provided by the manufacturer (Promega, Madison, WI). 
Compounds 1 and 2 induce apoptosis in cancer cells
To determine the molecular mechanism by which the com pound 1 and 2 inhibit cancer cell proliferation, we further analyzed the cytotoxicity of the compound 1 and 2 in PC 3 cells. As shown in Fig. 2 , both compound 1 and 2 induced PC 3 cell death could be clearly observed. To determine whether the decreased viability of PC 3 cells was due to the compound 1 or 2 induced apoptosis, the cells were treated with the compound 1 or 2, and subjected to Annexin V analysis. The translocation of membrane phospho lipid phosphatidylserine (PS) from the inner to the outer leaflet of the plasma membrane is an early event of cell apoptosis.
Annexin V is a 35 36 kD Ca 2+ dependent, phospholipid binding protein that has a high affinity for PS. Therefore, FITC conjugated Annexin V is commonly used to determine apoptotic cells at an early stage. As shown in Fig. 3 , treatment with compound 1 and 2 resulted in 35.2% and 61.5% PI/Annexin V double labeled apopto tic cells after 24 h incubation, suggesting both compounds are a potent apoptotic inducer in prostate cancer cells. The similar result was observed after PC3 cells were treated with compound 1 and 2 in a dose dependent manner (Fig. 4) . Treatment with 10 lg/mL of compound 1 for 24 h resulted in 42.2% PI/Annexin V double la beled apoptotic cells while compound 2 could produce 66.4% on the same condition, suggesting the compound 2 is more potent in induction of apoptosis in PC 3 cells. To further evaluate compound 1 induced apoptosis in prostate cancer cells, we determined the activity of caspase 3 in the cells by a flow cytometry assay. Majority of the cells (81.28%) after 24 h treatment with the compound 1 exerted caspase 3 activity (Fig. 5) .
Cytochrome c is an electron transporting protein within the in ter membrane space of the mitochondria. It has been demon strated that cytochrome c plays an important role in apoptotic the intracellular portion of the receptor, resulting in the activation of caspase 8 and 3 the effector enzymes in cell apoptosis. The intrinsic apoptotic pathway is characterized by permeabilization of the mitochondria in the injured cells, resulting in release of cyto chrome c into the cytoplasm. Cytochrome c then forms a multi protein complex known as the 'apoptosome' and initiates activa tion of the caspase cascade through caspase 9. Activated caspase 9 cleaves and activates caspase 3, leading to apoptosis. Our results implicate that the compound 1 may induce apoptosis in PC 3 cells through activation of the intrinsic pathway although the exact molecular mechanism remains to be further elucidated.
Inhibitory effect on the growth of xenografted tumors
Clearly, compound 1 is able to induce apoptosis in prostate can cer cells. The potential to be a drug candidate is dependent of the effectiveness on tumor growth in vivo. To determine the therapeutic role of the compound 1 in tumor growth, PC 3 cells were implanted on the back near anterior limbs as described in the experimental section. The compound 1 dissolved in DMSO and diluted in PBS con taining 1% Tween 80 was intraperitoneally injected at the lower abdomen with 10 mg/kg body weight per day for five consecutive days. Obviously the compound was effective. The tumors on the mice treated with compound 1 were significantly growing slower. After termination of the experiment, the tumors were excised and weighed. As shown in Fig. 7A C, the average weight of tumors from mice treated with compound 1 was about 5.8 fold smaller than that in the control mice. The result suggests compound 1 may be a potent drug candidate for treating prostate cancer.
Conclusion
The antiproliferative activity of the new steroidal lactam 6 hydroximino 4 aza A homo cholest 3 one(1) and 6 hydroxyl 4 aza A homo cholest 3 one(2) against several cancer cell types was investigated. Our results revealed that the steroidal lactam compounds 1 and 2 displayed a distinct cytotoxicity against these cancer cells through effectively inducing cancer cell apoptosis by activation of the intrinsic pathway. Furthermore, the compound 1 inhibited tumor growth in an athymic mouse model, suggesting a potential for the compound to be a therapeutic drug candidate for prostate cancer treatment.
